Download PDF
Thromb Haemost 1997; 78(01): 742-746
DOI: 10.1055/s-0038-1657622
Newer antithrombotic agents
Schattauer GmbH Stuttgart

Thrombolytic Therapy

Désiré Collen
The Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
    PubMedGoogle Scholar
  • 2 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?. Blood 1994; 84: 680-686
    PubMedGoogle Scholar
  • 3 LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766
    CrossrefPubMedGoogle Scholar
  • 4 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
    CrossrefPubMedGoogle Scholar
  • 5 Collen D. Coronary thrombolysis:streptokinase or recombinant tissue-type plasminogen activator?. Ann Intern Med 1990; 112: 529-538
    CrossrefPubMedGoogle Scholar
  • 6 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
    CrossrefPubMedGoogle Scholar
  • 7 Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-36
    CrossrefPubMedGoogle Scholar
  • 8 Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Madison EL. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994; 8: 221-236
    PubMedGoogle Scholar
  • 10 International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995; 346: 329-336
    CrossrefPubMedGoogle Scholar
  • 11 Kawai C, Hosoda S, Motomiya T. et al, for the E6010 Investigators. Multicenter trial of a novel modified t-PA, E6010, by i.v. bolus injection in patients with acute myocardial infarction (AMI). Circulation 1992; 86: 001-409 (Abstract 1630).
    CrossrefPubMedGoogle Scholar
  • 12 Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674
    CrossrefPubMedGoogle Scholar
  • 13 Collen D, Stassen JM, Yasuda T, Refino CJ, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72: 098-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Cannon CP, McCabe CH, Gibson CM. et al. TNK-tissue plasminogen activator in acute myocardial infarction:results of the Thrombolysis in Myocardial Infarction (TIMI) lOAdose ranging trial. Circulation 1997; 95: 351-356
    CrossrefPubMedGoogle Scholar
  • 15 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jari D, Wang SP, Tung JS, Mark GE. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
    CrossrefPubMedGoogle Scholar
  • 16 Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-426
    CrossrefPubMedGoogle Scholar
  • 17 Haber E. Antibody targeting:a strategy for improving thrombolytic therapy. In: Molecular Cardiovascular Medicine. Haber E. ed. Scientific America; New York, NY: 1995. pp 145-155
    Google Scholar
  • 18 Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasminogen and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271: 27912-27918
    CrossrefPubMedGoogle Scholar
  • 19 Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De ManF, Benit E, Muyldermans L, Collen D, Van de WerfF. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049
    CrossrefPubMedGoogle Scholar
  • 20 Collen D, Zhao ZA, Holvoet P, Marijnen P. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992; 06: 226-231
    PubMedGoogle Scholar
  • 21 Collen D, Bernaerts R, Declerck PJ, De CockF, Demarsin E, Jenné S, Laroche Y, Lijnen HR, Silence K, Verstreken M. Recombinant staphylokinase variants with altered immunore-activity, I:Construction and characterization. Circulation 1996; 94: 197-206
    CrossrefPubMedGoogle Scholar
  • 22 Collen D, Moreau H, Stockx L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity, II:thrombolytic properties and antibody induction. Circulation 1996; 94: 207-216
    CrossrefPubMedGoogle Scholar
  • 23 Schlant (Chairman) RC. Reperfusion in acute myocardial infarction. Circulation 1994; 90: 2091-2102
    CrossrefPubMedGoogle Scholar